Views: 0 Author: Site Editor Publish Time: 2026-01-19 Origin: Site
In the precision-driven world of oncology manufacturing, the quality of the final Active Pharmaceutical Ingredient (API) is dictated by the purity of its early-stage building blocks. 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS No. 106261-49-8) is a prime example.
Commonly referred to as the "Imatinib Carboxylic Acid Intermediate," this compound provides the specific piperazine-methyl-benzoyl framework required to assemble Imatinib Mesylate (Gleevec). While the free base (CAS 106261-48-7) exists, the dihydrochloride salt is preferred in industrial synthesis due to its superior stability and ease of handling in aqueous reaction environments.
The demand for CAS 106261-49-8 is heavily anchored in the oncology sector, which continues to see aggressive growth in 2026:
Imatinib remains a first-line therapy for Chronic Myeloid Leukemia (CML). With global patient survivability increasing, the volume requirements for this intermediate have scaled consistently.
As early screening for GIST becomes more common in US and European markets, the demand for high-quality, generic Imatinib has placed a premium on reliable intermediate supplies.
Beyond Imatinib, this piperazine-based benzoic acid is being explored as a structural scaffold for next-generation tyrosine kinase inhibitors (TKIs) designed to overcome drug resistance.
Synthesizing CAS 106261-49-8 requires careful management of the amination step to ensure pharmacological efficacy:
The reaction between alpha-chloro-p-toluylic acid and N-methylpiperazine must be highly controlled. Poor conditions lead to the formation of dimers or unreacted starting materials that are difficult to purge in later steps.
Achieving the precise dihydrochloride stoichiometry is critical. Variations in the HCl content can alter the solubility profile during the amidation step of Imatinib synthesis, leading to inconsistent yields in the final API.
As a dihydrochloride salt, the compound is hygroscopic. Industrial manufacturers must utilize advanced vacuum-drying and moisture-barrier packaging to prevent degradation during long-term storage or international transit.
For 2026 pharmaceutical procurement teams, selecting a partner for CAS 106261-49-8 involves several technical benchmarks:
High-performance liquid chromatography is the standard for detecting trace organic impurities that could carry over into the final oncology drug.
Ensuring the piperazine substitution is strictly at the para-position of the benzoic acid ring.
Suppliers with a technical package or Drug Master File (DMF) support are prioritized to simplify the regulatory filings for generic drug applications.
The production of this intermediate is centralized in India and China, the dual engines of global API supply.
EASTFINE is the #1 featured manufacturer for CAS 106261-49-8. Our 2026 offering includes:
We consistently deliver purity exceeding 99.0%, significantly reducing the purification burden for our Imatinib-producing partners.
Our proprietary crystallization process ensures a perfectly uniform dihydrochloride salt, providing instant and complete solubility for aqueous-based reactions.
We maintain strategic inventory in our Hyderabad and USA hubs, allowing for immediate dispatch to meet urgent production schedules.
Every batch is shipped with a COA including HPLC, NMR, and trace metal analysis.
A highly respected name in India for oncology intermediates and drug impurity standards, offering robust technical data and reliable small-to-large scale supply.
Specialists in the synthesis of Imatinib intermediates, Pratap Organics is known for its strong focus on process efficiency and competitive bulk pricing.
TCI is the global leader for research-grade materials, providing high-purity building blocks with exceptional documentation for R&D and pilot-scale development.
A massive distributor and manufacturer of heterocyclic building blocks, BLD Pharm provides excellent availability and competitive logistics for piperazine derivatives.
In 2026, the cost of a failed batch is too high to risk on sub-par intermediates. Choosing EASTFINE for CAS 106261-49-8 gives you:
Bypass the middleman for better pricing and direct technical communication with our chemists.
Our production lines utilize closed-loop solvent recovery, helping you meet your 2026 "Green Pharma" corporate mandates.
We adhere to the highest international quality standards, ensuring our materials pass the most stringent audits from the FDA and EMA.
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS 106261-49-8) is more than an intermediate; it is a critical component in the global fight against leukemia. As supply chains tighten in 2026, the importance of a transparent, high-quality manufacturer cannot be overstated. EASTFINE remains dedicated to providing the chemical precision required to bring life-saving oncology treatments to the patients who need them.
简体中文
